Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Iovance Biotherapeutics (IOVA) over the last 10 years, with Sep 2025 value amounting to $361.9 million.

  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) rose 19.22% to $361.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.9 million, marking a year-over-year increase of 19.22%. This contributed to the annual value of $304.8 million for FY2024, which is 19.09% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $361.9 million for Q3 2025, which was up 8.36% from $333.9 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Shares Outstanding (Weighted Average) registered a high of $361.9 million during Q3 2025, and its lowest value of $224.2 million during Q1 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Shares Outstanding (Weighted Average) value was $279.8 million (recorded in 2024), while the average stood at $285.8 million.
  • Data for Iovance Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 24.68% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $255.9 million in 2023, then rose by 19.09% to $304.8 million in 2024, then increased by 19.22% to $361.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $361.9 million for Q3 2025, versus $333.9 million for Q2 2025 and $327.9 million for Q1 2025.